drugset / Trial / NCT01258933
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find out if ofatumumab can control CLL or SLL that is left after chemotherapy or chemoimmunotherapy. The safety of the drug will also be studied.
Timeline
- Start
- 2011-07-06
- Primary completion
- 2024-10-18
- Completion
- 2024-10-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ofatumumab | Monoclonal antibody | 1000 mg | Intravenous |